{"entity":{"id":"minocycline","kind":"drug","name":"Minocycline","aka":[],"tldr":"Minocycline is an antibiotic tablet used, like doxycycline, to make the acne-like rash from EGFR-blocking cancer drugs milder.","summary":"The US label covers bacterial infections. The MASCC EGFR inhibitor guideline (2011) reports that \"prophylactic minocycline 100 mg daily is an effective agent in reducing the number of lesions during the first 8 weeks\" and that minocycline \"is less photosensitizing, thus preferable in geographic or seasonal locations with a high UV index\". The amivantamab label names doxycycline or minocycline, 100 mg twice daily, from day 1 for 12 weeks. The Minocin NDA was approved on 26 October 1972.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Minocycline","links":[{"label":"US label (DailyMed): minocycline capsules","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0760232b-21a6-2b13-e063-6394a90a22c1"},{"label":"Lacouture et al., MASCC clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities (Support Care Cancer 2011)","url":"https://doi.org/10.1007/s00520-011-1197-6"},{"label":"US label (DailyMed): Rybrevant (amivantamab), rash prophylaxis","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1466c070-9f97-4fa4-a955-6a6b59981fb8"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["doxycycline","amivantamab"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["rash-skin-toxicity"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Minocin","modality":"Tetracycline-class antibacterial (oral)","supportive":true,"mechanism":"A tetracycline-class antibacterial, used in acneiform rash for its anti-inflammatory as well as antibacterial effect.","approvals":[{"region":"US","year":1972,"indication":"Bacterial infections listed on the label","note":"Year is the Minocin NDA 050444 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/minocycline/","neighbours":{"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"doxycycline","kind":"drug","name":"Doxycycline","route":"/drugs/doxycycline/"}],"term":[{"id":"rash-skin-toxicity","kind":"term","name":"Rash and skin toxicity (acneiform rash, paronychia)","route":"/terms/rash-skin-toxicity/"}]}}